2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working Party

Abstract

In this Special Report, Cloos and colleagues present the 2025 European LeukemiaNet measurable residual disease (MRD) consensus recommendation for acute myeloid leukemia (AML), providing a unified framework for standardizing and clinically applying MRD assessment in AML. These guidelines outline preferred assay selection, analysis strategies, and key parameters including timing, tissue type, and cutoffs across molecular subtypes, and define MRD levels with corresponding clinical recommendations to enhance patient care.